U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951463) titled 'A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer' on Nov. 16.

Brief Summary: To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.

Study Start Date: Dec. 31

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer

Intervention: DRUG: Glumetinib Tablets

Glumetinib 300 mg QD orally under fasting conditions

DRUG: Placebo

Placebo 300 mg QD orally under fasting conditions

DRUG: Osimertinib Mesylate Tablets

Administered orally...